The former has been used to evaluate the therapeutic potential in KRAS G12D-driven PDAC both in vitro and in vivo [234], whereas the latter has been found to be a promising tool for developing therapies to treat lung cancer harboring G12C and G12S mutations. The gene discussed is KRAS; the disease is lung carcinoma.